EPO received approval in 1989 from the U.S. Food and Drug Administration for clinical treatment of anemia associated with chronic renal failure due to insufficient EPO production, which has markedly improved treatment of this disease (Paoletti and Cannella, 2006; Jelkmann, 2013; Wright et al., 2015). The gene discussed is EPO; the disease is chronic kidney disease.